NMN (nicotinamide mononucleotide)
NAD+ precursor with one small human RCT in prediabetic postmenopausal women, newer than NR, generally comparable mechanism, regulatory ambiguity in some markets.
- Evidence
- Preliminary evidenceGRADE certainty: Low
- Typical dose
- 250–1,000 mg/day
- Time to effect
- The one trial ran 10 weeks
- Safety
- Has documented cautions
Evidence ratings summarise published research on NMN (nicotinamide mononucleotide) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.
Ask about NMN (nicotinamide mononucleotide)
Interactions
Taking any medication?
Check NMN (nicotinamide mononucleotide) against it.
Why
Nicotinamide mononucleotide (NMN) is a NAD+ precursor that has become widely available as a supplement, following animal studies of NAD+ precursors. The trial evidence here is one 10-week placebo-controlled, double-blind RCT (Yoshino 2021) in overweight or obese postmenopausal women with prediabetes, where NMN increased insulin-stimulated glucose disposal and muscle insulin signalling on a clamp while placebo produced no change. It is a single small trial with a physiological surrogate outcome, so it says little about other groups or clinical outcomes, and disease-endpoint trials are not yet available. NMN is not authorised as a novel food in the EU, so it may not be sold there as a food supplement; in the US it has been permitted in supplements since 2025.
How it works
Converted to NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase). Whether NMN itself is the active or whether it must be converted to nicotinamide riboside extracellularly before cellular uptake is debated (Slc12a8 transporter vs CD73-mediated pathway).
Expected onset · The one trial ran 10 weeks; clinical endpoints not established
How to take
Dosage
250–1,000 mg/day. Most current trials use 250–500 mg/day. Higher doses do not appear to add proportional benefit.
Timing
Once daily, morning; with or without food
On the label
Stated NMN content per dose. Third-party tested for purity (NMN supplements have had widely variable actual content per FDA testing). Refrigeration extends shelf life.
Studied in
Adults curious about NAD+ supplementation who accept that outcome data on ageing or longevity are absent.
Safety
Evidence
Yoshino 2021 Science RCT (placebo-controlled, double-blind, 10 weeks): in postmenopausal women with prediabetes who were overweight or obese, NMN increased insulin-stimulated glucose disposal on a hyperinsulinemic-euglycemic clamp and muscle insulin signalling, while placebo produced no change. This is a single small trial in one population, so it says little about other groups or longer-term outcomes.
GRADE certainty: Low — rated by Healicus using the GRADE method
No Cochrane review, no EMA monograph. Clinical-outcome trials remain small and short-duration. NMN supplement quality varies, FDA testing has found widely variable actual NMN content. Long-term safety beyond 1 year is not yet established.
Questions people ask
Does NMN (nicotinamide mononucleotide) work?
Yoshino 2021 Science RCT (placebo-controlled, double-blind, 10 weeks): in postmenopausal women with prediabetes who were overweight or obese, NMN increased insulin-stimulated glucose disposal on a hyperinsulinemic-euglycemic clamp and muscle insulin signalling, while placebo produced no change. This is a single small trial in one population, so it says little about other groups or longer-term outcomes. Certainty of the evidence: Low, rated by Healicus using the GRADE method.
How is NMN (nicotinamide mononucleotide) taken?
250–1,000 mg/day. Most current trials use 250–500 mg/day. Higher doses do not appear to add proportional benefit. Timing: Once daily, morning; with or without food. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.
Are there interactions or cautions?
Not authorised as a novel food in the EU. Few side effects were reported in the short trials. Long-term safety beyond 12 months is not yet established. Theoretical concern regarding chemotherapy interaction (NAD+ modulation in cancer cells). Coordinate with oncology. Pregnancy and breastfeeding: data not yet available; avoid. Documented drug and supplement interactions can be looked up in the free interaction reference.
What is the evidence based on?
Sources: Yoshino et al., Science 2021, nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.
One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.